Euronext Paris listed Ipsen, a global, mid-sized biopharmaceutical company focused on oncology, rare disease and neuroscience, is acquiring Nasdaq listed Epizyme, a US-based fully integrated, commercial-stage biopharmaceutical company. The transaction…






